Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227647 | 0.97 | HDAC1 (0.50) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL13227637 | 0.95 | HDAC1 (0.52) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL13227640 | 0.93 | NOTUM (0.51) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL13227804 | 0.85 | HDAC1 (0.56) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL13227806 | 0.85 | AKT1 (0.44) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL12627892 | 0.85 | NOTUM (0.42) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL13227799 | 0.84 | HDAC1 (0.44) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL13227811 | 0.84 | HDAC1 (0.44) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL14242456 | 0.84 | HDAC1 (0.44) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL12626928 | 0.84 | NOTUM (0.40) | NOTUMHDAC1HDAC6HDAC8SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | NOTUM 4169/4885HDAC1 3883/4885HDAC6 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.